Literature DB >> 12598396

Role of itraconazole in haematology/oncology.

N A Pandya1, A A Atra, U Riley, C R Pinkerton.   

Abstract

The antifungal agents most frequently used in prophylaxis and treatment are amphotericin B (and its new lipid forms) and azoles such as fluconazole, itraconazole, and more recently voriconazole. This review assesses the role of itraconazole in paediatric haematology/oncology practice. Its broader spectrum of activity and availability in oral and intravenous forms allow a flexible approach in the management of fungal infections.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12598396      PMCID： PMC1719494          DOI： 10.1136/adc.88.3.258

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  29 in total

Review 1.  The child with cancer and infection. II. Nonbacterial infections.

Authors:  P A Pizzo; M Rubin; A Freifeld; T J Walsh
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

2.  The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

Authors:  A Van Peer; R Woestenborghs; J Heykants; R Gasparini; G Gauwenbergh
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.

Authors:  M Nucci; I Biasoli; T Akiti; F Silveira; C Solza; G Barreiros; N Spector; A Derossi; W Pulcheri
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

4.  Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

Authors:  J L Harousseau; A W Dekker; A Stamatoullas-Bastard; A Fassas; W Linkesch; J Gouveia; R De Bock; M Rovira; W F Seifert; H Joosen; M Peeters; K De Beule
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Itraconazole pharmacokinetics in patients with renal dysfunction.

Authors:  J Boelaert; M Schurgers; E Matthys; R Daneels; A van Peer; K De Beule; R Woestenborghs; J Heykants
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 6.  The clinical pharmacokinetics of itraconazole: an overview.

Authors:  J Heykants; A Van Peer; V Van de Velde; P Van Rooy; W Meuldermans; K Lavrijsen; R Woestenborghs; J Van Cutsem; G Cauwenbergh
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

7.  Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels.

Authors:  M A Boogaerts; G E Verhoef; P Zachee; H Demuynck; L Verbist; K De Beule
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

Review 8.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

9.  Fungal infections in bone marrow transplant patients.

Authors:  J D Meyers
Journal:  Semin Oncol       Date:  1990-06       Impact factor: 4.929

Review 10.  Infection in cancer patients. A continuing association.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1986-07-28       Impact factor: 4.965
View more
  3 in total

1.  Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.

Authors:  Arne Simon; Mette Besuden; Sandra Vezmar; Carola Hasan; Dagmar Lampe; Sigrid Kreutzberg; Axel Glasmacher; Udo Bode; Gudrun Fleischhack
Journal:  Support Care Cancer       Date:  2006-08-30       Impact factor: 3.603

2.  Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.

Authors:  Stefanie Hennig; Claire E Wainwright; Scott C Bell; Hugh Miller; Lena E Friberg; Bruce G Charles
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.

Authors:  Mariana Nunes; Miguel Henriques Abreu; Carla Bartosch; Sara Ricardo
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.